- About the College
- Veterinary Medical Center
- Departments & Offices
Phase I Evaluation of STA-12-1474 in Canines with Spontaneous Cancer
To assess whether the compound STA-12-1474 has activity against specific canine cancers, including mast cell tumors, osteosarcomas, histiocytic sarcomas, and other carcinomas and sarcomas. Some of the parameters to be assessed are:
This clinical trial is sponsored by Synta Pharmaceuticals Corporation and evaluates the safety and effectiveness of a novel heat shock protein 90 (HSP90) inhibitor, STA-12-1474, when given to dogs with cancer. Heat shock protein 90 (HSP90) is a chaperone protein important in the maintenance and expression of several cell proteins critical for the survival and growth of many types of cancer cells. Studies have shown that HSP90 activity is increased in cancer cells and as such, inhibition of HSP90 activity would likely have damaging effects to cancer cells. This has been supported by several laboratory studies in which inhibition of HSP90 in different tumor cell lines results in cell death. STA-12-1474 is a novel HSP90 inhibitor that exhibits superior anti-tumor effectiveness in mouse models of cancer relative to previously used HSP90 inhibitors. This study is the first use of STA-12-1474 in dogs with cancer.
We are seeking to enroll up to 25 dogs who meet the following criteria:
We cannot enroll dogs who:
The treatment protocol involves administration of STA-12-1474 by intravenous injection over one hour once per week for 4 weeks. The first and last administration of STA-12-1474 require an overnight stay in the hospital to permit blood collection so STA-12-147 blood levels can be measured. Routine laboratory tests (bloodwork) and imaging studies (x-rays, ultrasound) will be performed at each visit to assess tumor size and potential response to therapy. Should a response to therapy occur, additional treatments with STA-12-147 will be offered.
If the dog meets the study criteria, there are no costs to the client. Al laboratory tests, diagnostic tests are covered, and if a side effect should occur, the costs for treatment are covered. If the dog fails to meet the requirements for enrollment, the client shall be liable for the costs of examination, lab work, and any imaging that may have been performed as part of the screening examination.
For more information on this study, contact:
Dr. Cheryl London
clinicaltrials [at] cvm [dot] osu [dot] edu